Health
Early monoclonal antibody therapies beneficial for COVID-19, finds study – News-Medical.Net
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB)…
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate coronavirus disease 2019 (COVID-19). The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19. The study is currently available on the medRxiv* preprint server.
Background
Since the emergence…
-
Noosa News24 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
Business22 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
Business23 hours agoDoes Macquarie rate BHP shares a buy after its FY25 results?
-
General18 hours agoMigrants raise concerns over Australia’s English tests for visa applicants